The polypill strategy in cardiovascular disease prevention: It's time for its implementation

Prog Cardiovasc Dis. 2023 Jul-Aug:79:37-40. doi: 10.1016/j.pcad.2023.03.003. Epub 2023 Mar 15.

Abstract

A polypill strategy has been demonstrated to improve treatment adherence in several cardiovascular disease (CVD) settings. However, data on the prognostic impact in the secondary prevention setting have been scarce. The Secondary Prevention of Cardiovascular Disease in the Elderly trial, the results of which have been recently published, has demonstrated a benefit in terms of major adverse CVD event reduction. This finding, in addition to previous evidence, should lead to a broader polypill implementation in CVD prevention.

Keywords: Atherosclerosis; Cardiovascular disease; Myocardial infarction; Polypill; Prevention.

Publication types

  • Review

MeSH terms

  • Aged
  • Cardiovascular Agents* / adverse effects
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / prevention & control
  • Drug Combinations
  • Humans
  • Secondary Prevention / methods

Substances

  • Cardiovascular Agents
  • Drug Combinations